Preliminary Investigation of Mitoxantrone Coating on Stent-Grafts to Inhibit Neointimal Proliferation
暂无分享,去创建一个
R. Erbel | O. Dirsch | U. Dahmen | Yanli Gu | Yuan Ji | H. Wieneke | I. A. Karoussos
[1] H. Kornhuber,et al. Treatment of multiple sclerosis with mitoxantrone , 2005, European Archives of Psychiatry and Clinical Neuroscience.
[2] S. Silber,et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. , 2004, Journal of the American College of Cardiology.
[3] R. Erbel,et al. Media remodeling--the result of stent induced media necrosis and repair. , 2004, VASA. Zeitschrift fur Gefasskrankheiten.
[4] D. Figgitt,et al. Mitoxantrone , 2004, CNS drugs.
[5] S. Silber. Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. , 2003, Journal of interventional cardiology.
[6] P. Serruys,et al. Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries , 2003, Circulation.
[7] A. Widmark. New principles in the treatment of prostate cancer--the oncologist's view. , 2003, Scandinavian journal of urology and nephrology. Supplementum.
[8] P. Fitzgerald,et al. 7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal Growth: An Intravascular Ultrasound Analysis From the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE) , 2002, Circulation.
[9] H. Bergmeister,et al. Biocompatibility and performance of the Wallstent and several covered stents in a sheep iliac artery model. , 2001, Journal of vascular and interventional radiology : JVIR.
[10] G. Rosen,et al. Recurrent gastrointestinal stromal sarcomas. , 2000, Surgical oncology.
[11] S. Stepkowski,et al. Molecular targets for existing and novel immunosuppressive drugs , 2000, Expert Reviews in Molecular Medicine.
[12] G. Rosen,et al. Surgical Resection and Intraperitoneal Chemotherapy for Recurrent Abdominal Sarcomas , 1999, Annals of Surgical Oncology.
[13] M. Leon,et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.
[14] R. Günther,et al. Iliac arteries: plain and heparin-coated Dacron-covered stent-grafts compared with noncovered metal stents--an experimental study. , 1997, Radiology.
[15] B. Dolmatch,et al. Patency and tissue response related to two types of polytetrafluoroethylene-covered stents in the dog. , 1996, Journal of vascular and interventional radiology : JVIR.
[16] W. Rostène,et al. Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model. , 1996, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[17] J. Powell,et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[18] S. Horwitz. Taxol (paclitaxel): mechanisms of action. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] R E Vlietstra,et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.
[20] U. Schuler,et al. Pharmacokinetics and Metabolism of Mitoxantrone A Review , 1990, Clinical pharmacokinetics.